Statera Biopharma Stock Current Valuation
| STABDelisted Stock | USD 0.04 0.0003 0.82% |
Valuation analysis of Statera Biopharma helps investors to measure Statera Biopharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Statera Biopharma's price fluctuation is not too volatile at this time. Calculation of the real value of Statera Biopharma is based on 3 months time horizon. Increasing Statera Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Statera Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Statera Pink Sheet. However, Statera Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0361 | Real 0.0343 | Hype 0.04 | Naive 0.0561 |
The real value of Statera Pink Sheet, also known as its intrinsic value, is the underlying worth of Statera Biopharma Company, which is reflected in its stock price. It is based on Statera Biopharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Statera Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Statera Biopharma helps investors to forecast how Statera pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Statera Biopharma more accurately as focusing exclusively on Statera Biopharma's fundamentals will not take into account other important factors: Statera Biopharma Company Current Valuation Analysis
Statera Biopharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Statera Biopharma Current Valuation | 12.92 M |
Most of Statera Biopharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Statera Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Statera Biopharma has a Current Valuation of 12.92 M. This is 99.91% lower than that of the Healthcare sector and 99.72% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.92% higher than that of the company.
Statera Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Statera Biopharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Statera Biopharma could also be used in its relative valuation, which is a method of valuing Statera Biopharma by comparing valuation metrics of similar companies.Statera Biopharma is currently under evaluation in current valuation category among its peers.
Statera Fundamentals
| Return On Equity | -2.87 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (5.73) % | ||||
| Current Valuation | 12.92 M | ||||
| Shares Outstanding | 54.66 M | ||||
| Shares Owned By Insiders | 15.93 % | ||||
| Shares Owned By Institutions | 5.41 % | ||||
| Number Of Shares Shorted | 1.25 M | ||||
| Price To Book | 0.16 X | ||||
| Price To Sales | 1.61 X | ||||
| Revenue | 1.49 M | ||||
| Gross Profit | 998.72 K | ||||
| EBITDA | (97.27 M) | ||||
| Net Income | (101.88 M) | ||||
| Cash And Equivalents | 506.1 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 10.62 M | ||||
| Debt To Equity | 0.23 % | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (0.20) X | ||||
| Cash Flow From Operations | (28.19 M) | ||||
| Short Ratio | 0.39 X | ||||
| Earnings Per Share | (0.76) X | ||||
| Number Of Employees | 46 | ||||
| Market Capitalization | 1.97 M | ||||
| Total Asset | 21.17 M | ||||
| Z Score | -13.2 | ||||
| Net Asset | 21.17 M |
About Statera Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Statera Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Statera Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Statera Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Statera Pink Sheet
If you are still planning to invest in Statera Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Statera Biopharma's history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |